Atlassian acquires Cenqua, drops .NET

Atlassian acquires Cenqua, drops .NET

Summary: Atlassian, makers of the JIRA issue tracker and Confluence enterprise wiki, has acquired Cenqua, makers of the popular Clover code coverage tool, and FishEye source repository viewer. The .NET version of Clover will be discontinued.

SHARE:
TOPICS: Open Source
0

Atlassian, makers of the JIRA issue tracker and Confluence enterprise wiki, has acquired Cenqua, makers of the popular Clover code coverage tool and FishEye source repository viewer. Cenqua's products will remain separate products in the Atlassian family, developed by the same team, but now with additional resources and support from the combined company.

Cenqua's founders, Peter Moore, Brendan Humphreys, Conor MacNeill and Matt Quail will all be moving to Atlassian's Sydney office. According to Peter, "We're really excited to be joining the Atlassian team. It's an awesome match that allows us to take our products further and apply Atlassian's global resources to product development and support." Peter will oversee all product development of the Cenqua product line including product management and engineering.

The .NET version of Clover will be discontinued in favor of the Java version, though existing users will receive support for 12 months from when they last purchased the product.

While Atlassian software itself is not open source, Atlassian supports open source developers with free licenses, so the free open source and community licenses that Cenqua has donated will remain unchanged.

Topic: Open Source

Ed Burnette

About Ed Burnette

Ed Burnette is a software industry veteran with more than 25 years of experience as a programmer, author, and speaker. He has written numerous technical articles and books, most recently "Hello, Android: Introducing Google's Mobile Development Platform" from the Pragmatic Programmers.

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Talkback

0 comments
Log in or register to start the discussion